pharma is the sole category represented across all 1 tracked stories. OSR Company is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Woori IO
pharma is the sole category represented across all 1 tracked stories. OSR Company is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention Woori IO, all published on March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Woori IO. Shared-story counts are live from our verified record — not editorial picks.
Woori IO, a subsidiary of OSR Company, has entered into a strategic Non-Disclosure Agreement (NDA) with Chinese pharmaceutical giant Sinopharm to explore commercialization opportunities in mainland China. The partnership also outlines a framework for collaboration on global multicenter clinical trials, signaling a major expansion for OSR's therapeutic pipeline into the world's second-largest pharmaceutical market.
